BD has entered a partnership with the U.S. government to expand domestic manufacturing and supply chain capacity for essential medical consumables.
The company intends to invest $19 billion in the U.S. over several years, including $3 billion toward U.S. manufacturing expansion, according to an Oct. 6 news release.
BD plans to expand U.S. production by approximately 5 billion essential medical consumables annually, raising its share of domestically supplied essential medical consumables to roughly 80%. It also intends to manufacture 100% of BD needles used in America domestically using American-made steel.
The agreement allows BD to be exempt from future Section 232 tariffs on covered BD products and inputs, subject to the final scope and implementation of future Section 232 actions and BD’s achievement of agreed milestones.
The announcement lands as hospital groups press for protection from tariffs on medical goods. The AHA asked USTR in July to exempt medications, medical devices and PPE from forced-labor tariffs, citing data showing 94% of plastic gloves and about half of medical devices used in the U.S. are imported. The federal government has also backed domestic production directly, with the Economic Development Administration investing $15.97 million in a Civica-led project to build a fully domestic supply chain for four sterile injectables.
